Off-label promotion

250. Big Pharm. The Great Big Drugs Rip-off (Part 3)

December 31, 2016

GlaxoSmithKline (GSK) In 2012, GSK agreed to plead guilty and to pay $3 billion to resolve its criminal and civil liability arising from the company’s unlawful promotion of certain prescription drugs, its failure to report certain safety data, and its civil liability for alleged false price reporting practices. This blog is based on the press […]

250. Big Pharm. The Great Big Drugs Rip-off (Part 3) Read More »

249. Big Pharm. The Great Big Drugs Rip-off (Part 2)

December 31, 2016

Johnson & Johnson In November the USA Department of Justice announced that Johnson & Johnson (J&J) would pay more than $2.2 billion as a result of criminal and civil offences in the way certain drugs were promoted and marketed. This blog has been prepared using material from the official press release issued on 4 November

249. Big Pharm. The Great Big Drugs Rip-off (Part 2) Read More »